Matthew Galsky, MD
Enriched profileProfessor of Medicine (Hematology and Medical Oncology) and Professor of Urology; Director of Genitourinary Medical Oncology and Deputy Director, Mount Sinai Tisch Cancer Center; Co-Director, Center of Excellence for Bladder Cancer · Tisch Cancer Institute
Matthew Galsky is Professor of Medicine (Hematology and Medical Oncology) and Professor of Urology; Director of Genitourinary Medical Oncology and Deputy Director, Mount Sinai Tisch Cancer Center; Co-Director, Center of Excellence for Bladder Cancer at Tisch Cancer Institute. OpenAlex indexes 888 publications with 35,299 citations (h-index 80); ClinicalTrials.gov lists 21 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Medical Oncology profiles in the findmyKOL directory.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Matthew Galsky, MD, is Professor of Medicine (Hematology and Medical Oncology) and Professor of Urology at Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai / The Mount Sinai Hospital, New York, NY. The public record shows 888 publications with 35,299 citations (h-index 80), centered on Bladder / Urothelial Cancer, Prostate Cancer. It also documents an investigator role on 21 registered clinical trials, industry payments reported by 22 companies, 3 NIH-funded awards (2015–2025).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Bladder / Urothelial Cancer
- 21 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 21 registered studies on ClinicalTrials.gov. The most recent:
- Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Samsung Bioepis Co., Ltd.Program year20251 payment
- PFIZER INC.Program year20252 payments
- Merck Sharp & Dohme LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Corticosteroid100%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2015–2025 per NIH RePORTER. The latest:
- Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
Icahn School of Medicine at Mount Sinai
FY2024$668,229R01CA249175 - Clinical Protocol and Data Management
Icahn School of Medicine at Mount Sinai
FY2024$280,419P30CA196521
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial.
Clinical cancer research
Clinical Trial2026 - Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer.
Cancer research communications
Article2026 - A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer.
Cancer discovery
Article2026 - TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
Future oncology (London, England)
Clinical Trial2026 - Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102).
JCO oncology advances
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/matthew-galsky-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/matthew-galsky-979b688
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - X / Twitter
x.com/mattgalsky
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Other
bcan.org/staff/matthew-galsky-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →bcan.org ↗ - Other
scholars.mssm.edu/en/persons/matthew-galsky
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholars.mssm.edu ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doctor.webmd.com ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →europeanurology.com ↗
- Director
Genitourinary Medical Oncology, Tisch Cancer Institute, Mount Sinai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗ - Deputy Director
Mount Sinai Tisch Cancer Center (NCI-Designated Comprehensive Cancer Center)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →drugtargetreview.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Secondary affiliations
appointments beyond the home institution- Professor of Urology
Icahn School of Medicine at Mount Sinai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗ - Cancer Clinical Investigation Program / Graduate School of Biomedical Sciences
Icahn School of Medicine at Mount Sinai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Media & interviews
press, podcasts and appearances- Recurring video-interview contributor on UroToday
e.g. "Adjuvant Nivolumab in High-Risk Muscle-Invasive Bladder Cancer …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →urotoday.com ↗ - OncLive On Air podcast segment
"FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Peter Carroll, MD
University of California, San Francisco